Internal Medicine, Medical Oncology · Palm Springs, FL
NPI
1417116211
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4801 S Congress Ave Ste 400
Palm Springs, FL, 33461
Phone (561) 366-4100
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.3M
209,121 services
Medicare patients, 2024
883
Average age 76
Drug cost, 2024
$3.8M
1,841 prescriptions
Company payments, 2025
$2,345
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elizabeth A Byron was code J9271 (injection, pembrolizumab, 1 mg), 25,200 times for 22 patients. In total Elizabeth A Byron billed 209,121 services in 160 codes, and Medicare paid $3.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 25,200 | 22 | $44.50 | $1.1M |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 18,360 | 21 | $0.29 | $5,241 |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 18,060 | 15 | $0.21 | $3,882 |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 12,360 | 13 | $0.27 | $3,383 |
| J1756 Injection, iron sucrose, 1 mg | Office | 8,500 | 18 | $0.18 | $1,519 |
| J0185 Injection, aprepitant, 1 mg | Office | 5,850 | 16 | $1.34 | $7,835 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 5,200 | 58 | $0.10 | $506 |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 5,100 | 13 | $2.29 | $12K |
| J0897 Injection, denosumab, 1 mg | Office | 4,440 | 27 | $20.51 | $91K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,890 | 14 | $6.42 | $19K |
| 85025 Blood Count | Office | 2,540 | 650 | $7.58 | $19K |
| 36415 Venipuncture Blood Collection | Office | 2,155 | 647 | $8.63 | $19K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,760 | 40 | $0.09 | $155 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,700 | 13 | $16.05 | $27K |
| 99214 Office E&M - Established | Office | 1,475 | 475 | $98.17 | $145K |
By year: 2022 $3.1M for 246,992 services; 2023 $2.8M for 217,741 services; 2024 $3.3M for 209,121 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,540 | 650 | $7.58 | $19K |
| 36415 Venipuncture Blood Collection | 2,155 | 647 | $8.63 | $19K |
| 85045 Blood Count | 87 | 68 | $3.84 | $334 |
| 81003 Clinical Chemistry | 42 | 18 | $2.20 | $92.4 |
Medicare prescription drug claims, 2024
In 2024, the drug Elizabeth A Byron prescribed most often to Medicare patients was Anastrozole, with 418 prescriptions and refills. In total Elizabeth A Byron wrote 1,841 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 418 | 1,037 | 145 | $7,176 |
| Letrozole Generic | 131 | 312 | 45 | $2,996 |
| Tamoxifen Citrate Generic | 96 | 249 | 33 | $1,831 |
| Eliquis Apixaban | 88 | 96 | 20 | $56K |
| Exemestane Generic | 65 | 143 | 22 | $6,932 |
| Ondansetron Odt Ondansetron | 58 | 59 | 43 | $1,252 |
| Allopurinol Generic | 48 | 94 | 21 | $336 |
| Verzenio Abemaciclib | 45 | 45 | Under 11 | $680K |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 43 | 48 | 13 | $202 |
| Gabapentin Generic | 41 | 47 | 14 | $364 |
| Imbruvica Ibrutinib | 35 | 35 | Under 11 | $474K |
| Lorazepam Generic | 34 | 38 | 11 | $116 |
| Dexamethasone Generic | 33 | 33 | Under 11 | $172 |
| Potassium Chloride Generic | 32 | 36 | 17 | $52.72 |
| Inlyta Axitinib | 29 | 29 | Under 11 | $448K |
Brand drugs: 377 claims; generic drugs: 1,464 claims; opioid claims: 51.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elizabeth A Byron $2,345 ($2,345 in general payments such as food, travel and fees) from 28 companies. The largest payer was Abbvie Inc. with $387.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 18 | $387 |
| Janssen Biotech, Inc. JNJ | 20 | $372 |
| Novartis Pharmaceuticals Corporation NVS | 26 | $356 |
| Pfizer Inc. PFE | 13 | $147 |
| Daiichi Sankyo Inc. 4568.T | 6 | $142 |
| Celgene Corporation BMY | 5 | $117 |
| GlaxoSmithKline, LLC. GSK | 6 | $114 |
| Kite Pharma, Inc. GILD | 4 | $93.07 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $80.94 |
| Genentech USA, Inc. ROG.SW | 3 | $65.28 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.